Can HSP27 and HSP70 be used as biomarkers for chronic obstructive pulmonary disease diagnosis?

Autor: Wissam H. Joumaa, Hassan Abu Bass, Khalil Al Kwatly, Ahmad El Sabbah, Hanine Al Kayal, Hassan Khachfe, Wiam Ramadan

Publikováno v: 5.2 Monitoring Airway Disease.

Chronic Obstructive Pulmonary Disease (COPD) is one of the major causes of death worldwide and it is accompanied by increased levels of Heat Shock Proteins (HSPs) and inflammation (Hacker et al, 2009). The aim of this study was to determine, using En

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3976c96e6a501daf1ce09b0c9832c74
https://doi.org/10.1183/13993003.congress-2015.pa3971

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multidisciplinary approach to giant cell tumors of tendon sheath and synovium-A critical appraisal of literature and treatment proposal.

Autor: van der Heijden, Lizz, Gibbons, C.L. Max H., Hassan, A. Bass, Kroep, Judith R., Gelderblom, Hans, van Rijswijk, Carla S.P., Nout, Remi A., Bradley, Kevin M., Athanasou, Nick A., Dijkstra, P.D. Sander, Hogendoorn, Pancras C. W., van de Sande, Michiel A. J.

Publikováno v: Journal of Surgical Oncology; Mar2013, Vol. 107 Issue 4, p433-445, 12p

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Autor: Amaral AT; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Department of Pathology, Seville, Spain., Garofalo C; Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna, Italy., Frapolli R; Department of Oncology IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Manara MC; Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna, Italy., Mancarella C; Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna, Italy., Uboldi S; Department of Oncology IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Di Giandomenico S; Department of Oncology IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Ordóñez JL; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Department of Pathology, Seville, Spain., Sevillano V; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Department of Pathology, Seville, Spain., Malaguarnera R; Department of Health, University of Catanzaro, Catanzaro, Italy., Picci P; Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna, Italy., Hassan AB; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom., De Alava E; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Department of Pathology, Seville, Spain., D'Incalci M; Department of Oncology IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Scotlandi K; Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Rizzoli Institute, Bologna, Italy. katia.scotlandi@ior.it.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Mar 15; Vol. 21 (6), pp. 1373-82. Date of Electronic Publication: 2015 Jan 21.